Table 1 Demographic and clinical features for patients with ICI-IA and ICI-treated controls. Patient details are provided in this table. ICI: immune checkpoint inhibitor; NSCLC: Non small cell lung cancer; GI: gastrointestinal; GU: genitourinary; CDAI: clinical disease activity index
Variable | ICI-IA (N = 80) | ICI-treated controls (N = 36) |
|---|---|---|
Age | 61.4 (13.8) | 67 (7.9) |
Sex | Female: 49 Male: 31 | Female: 18 Male: 18 |
Race | White: 71 Black: 4 Asian: 4 Other: 1 | White: 29 Black: 6 Native American: 1 Other: 1 |
Cancer type | Melanoma: 28 Lung cancer: 20 GI cancer: 11 GU cancer: 4 Breast Cancer: 4 Squamous cell: 4 Other: 9 | NSCLC: 36 |
ICI class | PD-1/PD-L1: 54 CTLA-4: 2 Ipi/Nivo: 23 Nivo/Relatlimab: 1 | PD-1/PD-L1: 34 Ipi/Nivo: 2 |
Time ICI start to sample date (months) | 37.2 (32.0) | 18 (19.7) |
IRAE (for controls) | N/A | 19 (52.8%) |
CDAI | 17.2 (11.1) | N/A |
CDAI Category | Remission:2 Low: 21 Moderate: 35 High: 20 | N/A |
Tenosynovitis present | 15 (19.2%) | N/A |
Enthesitis Y/N | 23 (29.9%) | N/A |
Required csDMARDs for ICI-IA | 29 (36.3%) | N/A |
Required biologics for ICI-IA | 19 (23.8%) | N/A |
On steroids at time of serum sample for ICI-IA | 30 (37.5%) | N/A |
Persistent IA > 6 months post ICI cessation (N = 71) | 58 (81.7%) | N/A |